Literature DB >> 30912094

Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.

Julia E Kieckhaefer1, Flavio Maina2, Rebecca G Wells1,3, Kirk J Wangensteen1.   

Abstract

Hepatocellular carcinoma (HCC) is a devastating and prevalent cancer with limited treatment options. Technological advances have enabled genetic screens to be employed in HCC model systems to characterize genes regulating tumor initiation and growth. Relative to traditional methods for studying cancer biology, such as candidate gene approaches or expression analysis, genetic screens have several advantages: they are unbiased, with no a priori selection; can directly annotate gene function; and can uncover gene-gene interactions. In HCC, three main types of screens have been conducted and are reviewed here: (1) transposon-based mutagenesis screens, (2) knockdown screens using RNA interference (RNAi) or the CRISPR/Cas9 system, and (3) overexpression screens using CRISPR activation (CRISPRa) or cDNAs. These methods will be valuable in future genetic screens to delineate the mechanisms underlying drug resistance and to identify new treatments for HCC. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2019        PMID: 30912094     DOI: 10.1055/s-0039-1678725

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  7 in total

1.  Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF.

Authors:  Zhenzhen Chen; Tiankun Lu; Lan Huang; Zhiwei Wang; Zhongyi Yan; Yubo Guan; Wenjing Hu; Zusen Fan; Pingping Zhu
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

2.  rtcisE2F promotes the self-renewal and metastasis of liver tumor-initiating cells via N6-methyladenosine-dependent E2F3/E2F6 mRNA stability.

Authors:  Zhenzhen Chen; Lan Huang; Kaili Wang; Lulu Zhang; Xiang Zhong; Zhongyi Yan; Benyu Liu; Pingping Zhu
Journal:  Sci China Life Sci       Date:  2022-03-03       Impact factor: 10.372

Review 3.  Exploring liver cancer biology through functional genetic screens.

Authors:  Cun Wang; Ying Cao; Chen Yang; René Bernards; Wenxin Qin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-23       Impact factor: 46.802

Review 4.  Using CRISPR/Cas9 to model human liver disease.

Authors:  Michele Alves-Bezerra; Nika Furey; Collin G Johnson; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2019-10-25

5.  In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma.

Authors:  A M Vázquez Salgado; M E Preziosi; D Yin; A Holczbauer; A M Zahm; N Erez; J Kieckhaefer; D Ackerman; T P Gade; K H Kaestner; K J Wangensteen
Journal:  Gastro Hep Adv       Date:  2022-06-01

6.  The Dynamic Chromatin Architecture of the Regenerating Liver.

Authors:  Amber W Wang; Yue J Wang; Adam M Zahm; Ashleigh R Morgan; Kirk J Wangensteen; Klaus H Kaestner
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-10-17

Review 7.  Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma.

Authors:  Kirk J Wangensteen; Kyong-Mi Chang
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.